Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 882 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period C Clear all
Recruiting Phase 2Phase 3 Interventional

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

NCT07159841
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions
Atumelnant, Placebo
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Withdrawn Not applicable Interventional

Core Warming of COVID-19 Patients

NCT04426344
View directory record Official record
Conditions
COVID 19
Interventions
ensoETM device
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 2 Interventional

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

NCT00734292
View directory record Official record
Conditions
Mild to Moderate Asthma
Interventions
fluticasone propionate, formoterol fumarate, fluticasone propionate, formoterol fumarate
Drug · Other
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Anaheim, California • Mission Viejo, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

NCT06456411
View directory record Official record
Conditions
Breast Carcinoma, Kidney Carcinoma, Carcinoma
Interventions
Functional Near-Infrared Spectroscopy, Questionnaire Administration, Virtual Technology Intervention, Cold Stimulation
Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Absorption of Bioactive Berberine in Human

NCT03438292
View directory record Official record
Conditions
Healthy
Interventions
Berberine, TPGS emulsified berberine, Quillaja extract emulsified berberine
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction

NCT00532844
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Sapropterin Dihydrochloride, Sapropterin Dihydrochloride and Vitamin C
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects

NCT04032834
View directory record Official record
Conditions
Asthma
Interventions
VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece, VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Combination Product
Lead sponsor
Vectura Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Tempe, Arizona • Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

NCT03030105
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects

NCT05526742
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CKD-510 capsule (reference), CKD-510 tablet (test)
Drug
Lead sponsor
Chong Kun Dang Pharmaceutical
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

NCT01754116
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral, GSK1265744 400 mg (200 nm), GSK1265744 400 mg (1 micro m), GSK1265744 400 mg (5 micro m)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 31, 2026, 3:02 AM EDT
Recruiting Phase 4 Interventional

International Care Bundle Evaluation in Cerebral Hemorrhage Research

NCT06429332
View directory record Official record
Conditions
Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions
Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care
Other · Diagnostic Test
Lead sponsor
Region Skane
Other
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

NCT04128293
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254 Tablet, GSK3640254 Capsule
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

NCT03068754
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Acthar, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

NCT02738931
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA), Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CSD201002: Study to Assess Nicotine Uptake From P10 Nicotine Pouches

NCT05081154
View directory record Official record
Conditions
Smoking, Tobacco Use
Interventions
Product A, Product B, Product C, Product D, Product E, Product F, Product G
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Phase 4 Interventional Results available

Outpatient Recovery From Acute Kidney Injury Requiring Dialysis

NCT05158153
View directory record Official record
Conditions
Acute Kidney Injury, Dialysis Hypotension
Interventions
ORKID Bundled Intervention, Furosemide
Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 4 Interventional Results available

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03227445
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

IVIG (Gamunex-C) Treatment Study for POTS Subjects

NCT03919773
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
IVIG, Albumin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

NCT04506905
View directory record Official record
Conditions
Schizophrenia
Interventions
Elpipodect, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
6
States / cities
Rogers, Arkansas • Glendale, California • Long Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Not applicable Interventional

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

NCT01505569
View directory record Official record
Conditions
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions
Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Drug · Biological · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

NCT01191723
View directory record Official record
Conditions
Healthy
Interventions
MAP0004, Inhaler Placebo, Moxifloxacin, Placebo Capsule
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glycomacropeptide and Women's Health

NCT05551091
View directory record Official record
Conditions
Obesity
Interventions
glycomacropeptide (GMP)
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 90 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants

NCT01662999
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

The Feasibility of a Comprehensive Behavioral Intervention in Patient Post TKA

NCT01799772
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
Comprehensive Behavioral Intervention, Standard of Care Exercise Program
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Oct 31, 2026, 3:02 AM EDT